Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non-Small-Cell Lung Cancer

Clinical Lung Cancer

Volumn 16, Issue 5, 2015, Pages 385-390

  Kitazono, Satoru ^a,b   Fujiwara, Yutaka ^a   Tsuta, Koji ^a   Utsumi, Hirofumi ^a   Kanda, Shintaro ^a   Horinouchi, Hidehito ^a   Nokihara, Hiroshi ^a   Yamamoto, Noboru ^a   Sasada, Shinji ^a   Watanabe, Shun Ichi ^a   Asamura, Hisao ^a   Tamura, Tomohide ^a   Ohe, Yuichiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Concordance rate; Immunohistochemistry; Operative; Surgical procedures

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMPUTED TOMOGRAPHY GUIDED NEEDLE BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SCORING SYSTEM; TRANSBRONCHIAL ASPIRATION; TRANSBRONCHIAL BIOPSY; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; BIOPSY; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84941418939     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.03.008     Document Type: Article

References (26)

1. M. Maemondo, A. Inoue, K. Kobayashi, et al. for the North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
2. T. Mitsudomi, S. Morita, Y. Yatabe, et al. for the West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
3. A.T. Shaw, B.Y. Yeap, B.J. Solomon, and et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis Lancet Oncol 12 2011 1004 1012
4. C. Zhou, Y.L. Wu, G. Chen, and et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
5. G. Scagliotti, R.A. Stahel, R. Rosell, N. Thatcher, and J.C. Soria ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development Eur J Cancer 48 2012 961 973
6. C. Quinton, and P.M. Ellis An evidence-based approach to the use of predictive biomarkers in the treatment of non-small cell lung cancer (NSCLC) Cancers (Basel) 3 2011 3506 3524
7. W.D. Travis, and N. Rekhtman Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing Semin Respir Crit Care Med 32 2011 22 31
8. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
9. G.J. Freeman, A.J. Long, Y. Iwai, and et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 2000 1027 1034
10. S.Y. Tseng, M. Otsuji, K. Gorski, and et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells J Exp Med 193 2001 839 846
11. Y. Latchman, C.R. Wood, T. Chernova, and et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation Nat Immunol 2 2001 261 268
12. H. Nishimura, M. Nose, H. Hiai, N. Minato, and T. Honjo Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor Immunity 11 1999 141 151
13. T. Okazaki, and T. Honjo PD-1 and PD-1 ligands: from discovery to clinical application Int Immunol 19 2007 813 824
14. H. Dong, S.E. Strome, D.R. Salomao, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat Med 8 2002 793 800
15. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, and N. Minato Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci U S A 99 2002 12293 12297
16. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 2004 5094 5100
17. C.Y. Mu, J.A. Huang, Y. Chen, C. Chen, and X.G. Zhang High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 2011 682 688
18. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
19. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
20. J.C. Soria, A. Mauguen, M. Reck, and et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 24 2013 20 30
21. P. Goldstraw, J. Crowley, K. Chansky, et al. for the International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 2007 706 714
22. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1977 159 174
23. J.M. Boland, E.D. Kwon, S.M. Harrington, and et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung Clin Lung Cancer 14 2013 157 163
24. J.D. Wolchok, H. Kluger, M.K. Callahan, and et al. Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
25. J.M. Taube, R.A. Anders, G.D. Young, and et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra137
26. E.A. Akbay, S. Koyama, J. Carretero, and et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Discov 3 2013 1355 1363